Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

20 Sept 2023

Abstract excerpt

ABSTRACT: The translocation t(11;14) occurs in 20% of patients with multiple myeloma (MM) and results in the upregulation of CCND1. Nearly two-thirds of t(11;14) MM cells are BCL2 primed and highly responsive to the oral BCL2 inhibitor venetoclax. Although it is evident that this unique sensitivity to venetoclax depends on the Bcl-2 homology domain 3- proapoptotic protein priming of BCL2, the biology underlying...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37729611
DOI: 10.1182/blood.2023020276

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependencyPMID 37729611Read ↗

Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocationSemantic proximity Read ↗

Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).Semantic proximity Read ↗

Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple MyelomaSemantic proximity Read ↗

Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myelomaSemantic proximity Read ↗

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomicsSemantic proximity Read ↗

Dynamic super-enhancer core regulatory circuits and epigenetic landscapes drive malignant progression and refractory disease in multiple myelomaSemantic proximity Read ↗

Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaSemantic proximity Read ↗

Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic ModificationsSemantic proximity Read ↗

Profound CD4+ T-Cell Reprogramming by Melphalan-Driven Oxidative Stress in High-Risk Multiple MyelomaSemantic proximity Read ↗

Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical featuresSemantic proximity Read ↗

Functional Impact of Genomic Complexity on the Transcriptome of Multiple MyelomaSemantic proximity Read ↗

Genetic program activity delineates risk, relapse, and therapy responsiveness in Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.